Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.41 |
| ▸ | NT5E | P21589 | 2/20 | 0.40 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.38 |
| ▸ | AHCY | P23526 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14023346 | 0.94 | HINT1 (0.42) | HINT1CYP1A2STING1P2RY11 | |
| SCHEMBL5425043 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL5216986 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL5216981 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL6788532 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL14023347 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL5435997 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL9202661 | 0.92 | NT5E (0.41) | HINT1CYP1A2STING1NT5E | |
| SCHEMBL5217050 | 0.91 | HINT1 (0.40) | HINT1CYP1A2STING1 | |
| SCHEMBL14023348 | 0.91 | HINT1 (0.40) | HINT1CYP1A2STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | BELLEAU BERNARD | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037977-A1 | Substituted-1, 3-oxathiolanes and substituted-1, 3-dioxolanes with antiviral properties | IFNAR1, MAVS, IFNG | HINT1 996/4885CYP1A2 1337/4885STING1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.